Pall Corporation Acquires BioSMB Technology from Tarpon Biosystems to Expand Downstream Continuous Processing Capabilities
![](/46/pdcnewsitem/03/43/34/kuHqTXNEBZqQ70j.png)
Pall Corporation has announced the acquisition of the BioSMB technology platform from Tarpon Biosystems. These chromatographic systems enable single-use, multicolumn chromatography for process development and are well placed for multiproduct and single-use facilities.
BioSMB technology is fully scalable from process development to large scale GMP production. The disposable flow path features a proprietary integrated valve cassette and services up to 16 columns or devices.
“We are pleased to add this cutting-edge technology to our growing portfolio of products and services. It extends our process intensification and continuous processing capabilities to support customers as they adopt continuous downstream processing,” said Ken Frank, senior vice president at Pall Life Sciences. “The BioSMB technology incorporates disposable components to enable flexible, multiproduct biomanufacturing while reducing costs.”
Nelson K. Stacks, president of Tarpon Biosystems further stated: " With this acquisition the strength and reputation of Pall will enable an even wider adoption of the BioSMB platform."
This latest addition expands Pall’s portfolio in continuous processing technology at both the process development and GMP scales of operation, while complementing existing Allegro single-use products and systems.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance